found TYMS polymorphisms influence on tumor response and toxicities derived from irinotecan plus 5-fluorouracil treatment in CRC patients, and proposed a genetic-based algorithm to optimize treatment individualization (73). The gene discussed is TYMS; the disease is colorectal carcinoma.